Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study, Evaluating the Safety, Tolerance and Efficacy of PRJ1-3024 Capsules in China Subjects with Unresectable Local Advanced or Metastatic Melanoma

NCT06727630 is registered in ClinicalTrials.gov with Zhuhai Yufan Biotechnologies Co., Ltd as lead sponsor.

NCT NCT06727630
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06727630 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study, Evaluating the Safety, Tolerance and Efficacy of PRJ1-3024 Capsules in China Subjects with Unresectable Local Advanced or Metastatic Melanoma
Lead sponsor
Zhuhai Yufan Biotechnologies Co., Ltd
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 14, 2024
Completion date
October 30, 2025
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma